Another highly specific, structurally distinct Menin–KMT2A interaction inhibitor, VTP50469, has also shown nanomolar‐range activity, effectively suppressing KMT2A‐target gene expression and cell proliferation in KMT2A‐rearranged leukemia models.98 The gene discussed is KMT2A; the disease is leukemia.